Since the Food and Drug Administration blasted Novartis (NVS) earlier this month over data manipulation, one of the major questions looming over the matter has been why the agency came down so publicly on the drug maker. The answer, according to a top FDA official, is because the stakes were too high to do otherwise.

Dr. Peter Marks, who wrote the statement that created a storm of controversy around Novartis and data used to support approval of the drug Zolgensma, said in an interview that any case in which data are mishandled and patients are harmed could set the whole field of gene therapy back, just as the death of a patient, Jesse Gelsinger, froze research two decades ago.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Z is not approved in Europe, and now will take longer to do so, because of this appalling lack of seriousness? frankness? candor? honesty? from Novartis. If the drug works, Europeans will not have access until much longer than anticipated. If it doesn’t work, good job FDA, for spotting inconsistencies! With 800 (?) other gene therapies in line, let’s get our pharmaceutical act – I wanted to say something else – together! This is unacceptable from an end-user (patient) point of view.

  • Most surely i have written and or stated sufficient responses to this one more of the Health Care .System or Industry . with This Nation , The United States Of America , that which most of not all are predicated with the intent for blood money profits Primarily . rather than the health and safety of humans by The Pharmaceutical Empires , The Chain Hospitals . The Bribed Drug Dealers Doctors In White Coats and The Pharmacies . The Novartis Current Issue is only one more example . I thank you Trevor Merchant . Bronx . New York City . Thursday . August . 22, 2019 at 3. 12 p.m . daylight savings time . N.Y.C

  • Once again Novartis caught with their pants down, you only have to Google how many fines they’ve had over the years to realise it’s how they do business.

  • Novartis screwed up ROYALLY and FDA acted which they are shy of doing repeatedly.

    Legislators can do all sorts of dance but at the end of the day they will drink from the same glass.

  • “why the agency came down so publicly on the drug maker. ” — Really? Instead of applauding some semblance of integrity (minor mind you, after all, Novartis simply gamed the FDA) we question why the FDA wagged the finger at the culprit? The entirety of the drug approval system is a farce where companies play the tune and the FDA dances.

  • Once again, it shows how out of control the regulations of fda have become. Marks admits that something which has no relevance to or impact on risk/benefit of a medication (“we got lucky” that this error does not really matter), WOULD have caused a delay to the approval of this medicine, had they known about it sooner. It is noteworthy that he doesn’t mention how much of a delay. A CRL could have delayed it by a year+. And how many would have lost the ability to walk and gone onto ventilators over the length of that delay?
    It only shows the review process (which takes the FDA 8 months or 12 months to do, and 2 of those months are just to confirm that all the required sections are within the application) has morphed into a bureaucratic mess.

    “We can’t make sure they do the experiments right” – such arrogance. Of course they can’t – they are too busy taking their sweet time over 12 months to review all that paperwork for each new drug application.
    The FDA employees responsible for reviewing the irrelevant portions of the applications (like whatever one is being referenced in this article and incident) have too much power to derail life saving medications.
    Until it is made clear what exactly happened with this particular bit of data, all we know is that something was “manipulated” and all we can say is that Novartis has to take responsibility (and they did, considering they fired those who did it). Beyond that we have no idea what actually happened and it could have been an honest mistake until proven otherwise.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy